BioDlink International Company Limited (stock code: 1875) issued an update regarding its relevant securities pursuant to Rule 3.8 of the Hong Kong Code on Takeovers and Mergers. According to the announcement, 142,000 share options vested on 1 March 2026.

Following this vesting, the company has 772.79 million shares in issue. Among these, 30.02 million are outstanding vested RSA shares for which the full consideration has not yet been received, and 14.56 million remain unvested. In addition, 7.63 million share options remain outstanding, of which 7.35 million are vested but unexercised, and 0.14 million remain unvested.

The announcement reminds all associates of the company and the offeror—including holders of 5% or more of the relevant securities—to comply with rule-based disclosure obligations during the offer period. It further cautions that completion of the offers is subject to fulfillment or waiver of certain conditions and may therefore not become unconditional.